Literature DB >> 33080454

Making "bad trips" good: How users of psychedelics narratively transform challenging trips into valuable experiences.

Liridona Gashi1, Sveinung Sandberg2, Willy Pedersen3.   

Abstract

BACKGROUND: We study the significance of stories about bad trips among users of psychedelics. Drawing on narrative theory, we describe the characteristics of such stories and explore the work they do.
METHODS: In-depth qualitative interviews with 50 Norwegian users of psychedelics.
RESULTS: Almost all participants had frightening experiences when using psychedelics and many described these as bad trips. The key feature of a bad trip was a feeling of losing oneself or going crazy, or ego dissolution. Most users said that these experiences could be avoided by following certain rules, based on tacit knowledge in the subcultures of users. Possessing such knowledge was part of symbolic boundary work that distinguished between drug culture insiders and outsiders. Some also rejected the validity of the term bad trip altogether, arguing that such experiences reflected the lack of such competence. Finally, and most importantly, most participants argued that unpleasant experiences during bad trips had been beneficial and had sometimes given them deep existential and life-altering insights.
CONCLUSION: Bad trip experiences are common among users of psychedelics. Such experiences are often transformed into valuable experiences through storytelling. Bad trip narratives may be a potent coping mechanism for users of psychedelics in non-controlled environments, enabling them to make sense of frightening experiences and integrate these into their life stories. Such narrative sense-making, or narrative work, facilitates the continued use of psychedelics, even after unpleasant experiences with the drugs.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Bad trip; DMT; LSD; Narratives; Psilocybin; Psychedelics

Year:  2020        PMID: 33080454     DOI: 10.1016/j.drugpo.2020.102997

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  7 in total

1.  From Underground to Mainstream: Establishing a Medical Lexicon for Psychedelic Therapy.

Authors:  Andrew Beswerchij; Dominic Sisti
Journal:  Front Psychiatry       Date:  2022-06-17       Impact factor: 5.435

2.  The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.

Authors:  Tomas Frymann; Sophie Whitney; David B Yaden; Joshua Lipson
Journal:  Front Psychol       Date:  2022-05-23

3.  Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.

Authors:  Madelene Palmer; Olivia M Maynard
Journal:  Harm Reduct J       Date:  2022-07-24

4.  Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.

Authors:  Emma I Kopra; Jason A Ferris; Adam R Winstock; Allan H Young; James J Rucker
Journal:  J Psychopharmacol       Date:  2022-04-07       Impact factor: 4.562

Review 5.  Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.

Authors:  Joost J Breeksema; Bouwe W Kuin; Jeanine Kamphuis; Wim van den Brink; Eric Vermetten; Robert A Schoevers
Journal:  J Psychopharmacol       Date:  2022-08-26       Impact factor: 4.562

Review 6.  3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs.

Authors:  Raúl López-Arnau; Jordi Camarasa; Marcel Lí Carbó; Núria Nadal-Gratacós; Pol Puigseslloses; María Espinosa-Velasco; Edurne Urquizu; Elena Escubedo; David Pubill
Journal:  Front Psychiatry       Date:  2022-10-03       Impact factor: 5.435

Review 7.  Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.

Authors:  Anne K Schlag; Jacob Aday; Iram Salam; Jo C Neill; David J Nutt
Journal:  J Psychopharmacol       Date:  2022-02-02       Impact factor: 4.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.